Product Name
Leucine Rich Repeat Kinase 2 (LRRK2), Polyclonal Antibody
Full Product Name
Cy3-Linked Polyclonal Antibody to Leucine Rich Repeat Kinase 2 (LRRK2)
Product Synonym Names
AURA17; PARK8; RIPK7; ROCO2; Dardarin ; Parkinson Disease (Autosomal Dominant)8; Leucine-rich repeat serine/threonine-protein kinase 2
Product Gene Name
anti-LRRK2 antibody
[Similar Products]
Matching Pairs
Unconjugated Antibody: Leucine Rich Repeat Kinase 2 (LRRK2) (MBS2005994)
Cy3 Conjugated Antibody: Leucine Rich Repeat Kinase 2 (LRRK2) (MBS2080200)
Matching Pairs
Cy3 Conjugated Antibody: Leucine Rich Repeat Kinase 2 (LRRK2) (MBS2080200)
Immunogen: Leucine Rich Repeat Kinase 2 (LRRK2) (MBS2012043)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Concentration
200ug/ml (lot specific)
Immunogen
LRRK2 (Phe1479~Pro1729)
Unconjugated Antibody
The unconjugated antibody version of this item is also available as catalog #MBS2005994
ISO Certification
Manufactured in an ISO 9001:2008 and ISO 13485:2003 Certified Laboratory.
Supply Chain Verification
Manufactured in a lab with traceable raw materials. Bulk orders can typically be prepared to the customerâs specifications, please inquire.
Other Notes
Small volumes of anti-LRRK2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-LRRK2 antibody
Western Blot (WB), Immunocytochemistry (ICC), Immunohistochemistry (IHC) Formalin/Paraffin, ELISA (ELISA)
NCBI/Uniprot data below describe general gene information for LRRK2. It may not necessarily be applicable to this product.
NCBI Accession #
AAI17181.1
[Other Products]
UniProt Secondary Accession #
Q6ZS50; Q8NCX9; A6NJU2[Other Products]
UniProt Related Accession #
Q5S007[Other Products]
Molecular Weight
286,103 Da
NCBI Official Full Name
Leucine-rich repeat kinase 2
NCBI Official Synonym Full Names
leucine rich repeat kinase 2
NCBI Official Symbol
LRRK2 [Similar Products]
NCBI Official Synonym Symbols
PARK8; RIPK7; ROCO2; AURA17; DARDARIN
[Similar Products]
NCBI Protein Information
leucine-rich repeat serine/threonine-protein kinase 2
UniProt Protein Name
Leucine-rich repeat serine/threonine-protein kinase 2
UniProt Synonym Protein Names
Dardarin
Protein Family
Leucine-rich repeat serine/threonine-protein kinase
UniProt Gene Name
LRRK2 [Similar Products]
UniProt Synonym Gene Names
PARK8 [Similar Products]
NCBI Summary for LRRK2
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008]
UniProt Comments for LRRK2
LRRK2: a large multidomain protein kinase with a TKL-type kinase domain, multiple protein-protein interaction domains and a mitochondrial Rho domain (MIRO). May play a role in the etiology of Parkinson disease. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Interacts with PARK2, PRDX3 and TPCN2. Expressed throughout the ***** brain, but at a lower level than in heart and liver. Expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas. Defects in LRRK2 are the cause of Parkinson disease type 8 (PARK8). A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.
Protein type: EC 2.7.11.1; Kinase, protein; LRRK family; Protein kinase, Ser/Thr (non-receptor); Protein kinase, TKL; TKL group
Chromosomal Location of Human Ortholog: 12q12
Cellular Component: axon; cell soma; cytoplasm; cytoplasmic vesicle; cytosol; dendrite; dendrite cytoplasm; endoplasmic reticulum; endosome; extracellular space; Golgi apparatus; Golgi-associated vesicle; growth cone; inclusion body; intracellular; lysosome; microvillus; mitochondrial inner membrane; mitochondrial matrix; mitochondrial membrane; mitochondrial outer membrane; mitochondrion; neuron projection; perikaryon; plasma membrane; terminal button
Molecular Function: actin binding; clathrin binding; glycoprotein binding; GTP binding; GTP-dependent protein kinase activity; GTPase activator activity; GTPase activity; identical protein binding; kinase activity; MAP kinase kinase activity; microtubule binding; protein binding; protein homodimerization activity; protein kinase A binding; protein kinase activity; protein serine/threonine kinase activity; receptor signaling complex scaffold activity; Rho GTPase binding; SNARE binding; syntaxin-1 binding; tubulin binding
Biological Process: activation of MAPK activity; activation of MAPKK activity; calcium-mediated signaling; cellular response to starvation; determination of ***** life span; endocytosis; Golgi organization and biogenesis; GTP metabolic process; intracellular distribution of mitochondria; lysosome organization and biogenesis; MAPKKK cascade; mitochondrion localization; mitochondrion organization and biogenesis; negative regulation of macroautophagy; negative regulation of protein amino acid phosphorylation; negative regulation of protein binding; neurite morphogenesis; neuromuscular junction development; olfactory bulb development; peptidyl-serine phosphorylation; peptidyl-threonine phosphorylation; phosphorylation; positive regulation of autophagy; positive regulation of dopamine receptor signaling pathway; positive regulation of MAP kinase activity; positive regulation of programmed cell death; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of protein amino acid phosphorylation; positive regulation of protein binding; positive regulation of protein ubiquitination; protein amino acid autophosphorylation; protein amino acid phosphorylation; regulation of autophagy; regulation of dopamine receptor signaling pathway; regulation of excitatory postsynaptic membrane potential; regulation of locomotion; regulation of membrane potential; regulation of mitochondrial depolarization; regulation of neuron maturation; regulation of synaptic transmission, glutamatergic; response to oxidative stress; tangential migration from the subventricular zone to the olfactory bulb; Wnt receptor signaling pathway through beta-catenin
Disease: Parkinson Disease 8, Autosomal Dominant
Research Articles on LRRK2
1. LRRK2 p.Gly2385Arg can explain most if not all of the PD association at rs1994090 in East Asians, but other nonsynonymous variants are independent.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.